Metraipolis › archive › dc_34db8b575aee
SARS-CoV-2 antibody and neutralization dynamics among persons with natural- and vaccine-induced exposures — Europe PMC PMID:40901824
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40901824
- DOI
- 10.1371/journal.pone.0331212
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T13:32:19.676Z
- SHA-256 of the archived text
682efb8d53531b43c1656c46a61cde77d8ad7353b8d2054f7dda2bdd06e6c974- Stable URL of this page
https://metraipolis.com/documento/dc_34db8b575aee
How to cite
SARS-CoV-2 antibody and neutralization dynamics among persons with natural- and vaccine-induced exposures — Europe PMC PMID:40901824 — Europe PMC (en), https://europepmc.org/article/MED/40901824 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_34db8b575aee (Metraipolis archive dc_34db8b575aee, sha256 682efb8d53531b43c1656c46a61cde77d8ad7353b8d2054f7dda2bdd06e6c974)
BibTeX
@misc{dc34db8b575aee,
title = {SARS-CoV-2 antibody and neutralization dynamics among persons with natural- and vaccine-induced exposures — Europe PMC PMID:40901824},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40901824},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_34db8b575aee; sha256 682efb8d53531b43c1656c46a61cde77d8ad7353b8d2054f7dda2bdd06e6c974},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40901824. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Previous SARS-CoV-2 research indicates that antibody levels and corresponding neutralization potential increase with additional exposures (comprising vaccination or infection), and that hybrid immunity resulting from combined vaccination and natural infection is more robust than either alone. However, it is unclear whether or how antibody levels increase or eventually plateau with repeated exposures and how SARS-CoV-2 exposure differs by sex or other demographic factors. Research regarding the association of antibody production with neutralization potential is also limited. We conducted this analysis within the RESPIRA population-based cohort in Costa Rica to investigate relationships between antibody levels and neutralization potential at increasing exposure levels. We examined immunological profiles from systematically defined single-exposure groups (one vaccine dose or one natural infection), double-exposure groups (two vaccine doses or one vaccine dose following a natural infection), and a triple-exposure group (two vaccine doses following a natural infection). We used a S1-RBD-based serological assay for antibody level detection and a pseudovirion assay for neutralization potential quantification. Using linear regression, we compared antibody levels and pseudoneutralization geometric mean titers between exposure groups. For single exposure groups, one vaccine dose was inferior to natural infection, but a second vaccine dose was superior to natural infection. For double exposure groups, those who were vaccinated once after infection developed higher levels of antibodies and higher neutralization potential compared with those who had only two vaccine doses. We note that peak antibody levels following an exposure may plateau after two exposures while neutralization potential continues to increase with a third exposure dose. Response patterns were comparable in males and females and in sensitivity analyses stratified by age, vaccine type, and pandemic wave. These results provide evidence that SARS-CoV-2 vaccination after COVID infection provides immunological benefit and suggest neutralization potential continues to increase after a second vaccine dose despite plateauing of antibody levels. Tema degli esploratori: scienze della vita e salute (ricerca Europe PMC «immunology», solo open access). Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-09-03). Identificativi: PMID 40901824 · PMCID PMC12407447 · DOI 10.1371/journal.pone.0331212. Descrittori MeSH principali: Antibodies, Viral; Antibodies, Neutralizing; COVID-19; SARS-CoV-2; COVID-19 Vaccines. Pagina: https://europepmc.org/article/MED/40901824 — https://doi.org/10.1371/journal.pone.0331212. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T13:04:06.445Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.